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Abstract
This review looks at osteonecrosis in the stomatognathic system (mainly the jaws). Osteonecrosis of the jaw (ONJ) is a rare but serious
clinical condition. It affects patients treated with bisphosphonates, and also with denosumab, mainly in oncological doses. In osteoporosis,
it is a problem of relatively small significance. Article presents a thorough review of this phenomenon, including its definition, pathogen-
esis, risk factors, prevention and treatment methods, and its incidence rate. (Pol J Endocrinol 2011; 62 (1): 88–92)
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Streszczenie
Praca poglądowa dotyczy osteonekrozy w układzie stomatognatycznym (głównie żuchwy). Osteonekroza żuchwy jest zjawiskiem rzad-
kim, ale poważnym. Dotyczy pacjentów leczonych bisfosfonianami, ale także denosumabem, głównie w dawkach onkologicznych.
W osteoporozie jest to problem o bardzo małym znaczeniu. W pracy przedstawiono: definicję, patogenezę, czynniki ryzyka, sposoby
zapobiegania i leczenia oraz częstość występowania tego zjawiska. (Endokrynol Pol 2011; 62 (1): 88–92)
Słowa kluczowe: osteonekroza żuchwy, bisfosfoniany, denosumab
Necrosis
From the pathological point of view, necrosis is a retro-
grade change, meaning death of cells or tissues in a live
organism. It is induced by the activities of injuring fac-
tors, which (either directly or indirectly) inhibit blood
supply to the tissues [1].
Osteonecrosis
Necrosis affects different tissues. When it affects osseous
tissue, it is referred to as osteonecrosis. It is always an
effect of acute ischemia, frequently resulting from: cor-
ticosteroid therapy (affecting mainly the femoral and
the humeral bone), mechanical injuries of vessels, e.g.
bone fractures, the presence of thrombi and embolisms
developing by various causes, and medical conditions
such as vasculitis or osteomyelitis [1].
There is also aseptic bone necrosis (avascular necro-
sis), which occurs in children and adolescents as a re-
sult of circulation disorders. This particular type of ne-
crosis is localised in the femoral head (Perthes disease),
the humeral head (Panner’s disease), vertebral bodies
(Scheuermann’s disease) or in the sternal end of the clav-
icle (Friedrich’s disease) [1].
Osteonecrosis in the stomatognathic system
Osteonecrosis may also affect bones in the stomatog-
nathic system, mainly the lower and upper jaw. The
most frequently observed medical conditions include:
— osteoradionecrosis (after X-ray therapeutic irradia-
tion of head and neck regions);
— osteonecrosis in the course of corticosteroid therapy;
— osteonecrosis in the course of osteomyelitis [2].
Recently, a new type of osteonecrosis of the jaws
(ONJ) has been described:
— osteonecrosis associated with the use of bisphos-
ponates (BP) (BP-induced osteonecrosis of the jaw,
BONJ). The first case of BONJ was described by Marx
in 2003 [3]. BONJ is a rare but serious medical con-
dition, which may occur in patients treated with bis-
phosphonates, mainly in oncological doses.
BONJ definition
Understanding the proper BONJ definition is impor-
tant, as it allows for its proper diagnosis.
BONJ is clinically characterised by exposed bones
in the mandibular, maxillary or palatal regions, the le-
sions either not healing at all or healing poorly over 6–8
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weeks. This condition concerns subjects treated with
bisphosponates, mainly in oncological doses, after ex-
clusion of roentgenotherapy applied in this particular
region, or a local neoplasmatic process [4–6].
Clinical features of BONJ
BONJ is characterised by defects of oral mucosa with
bone exposure (this lesion is usually painful). Usually,
the lesion occurs in the mandible (two thirds of cases)
or the maxilla (one third of cases) [5, 7, 8]. Very rarely, it
may affect the palate. A case report has been published
describing internal auditory meatus involvement [9] and
its course may be chronic and complicated.
BONJ has three intensity stages, which differ by
treatment mode (Table I) [10]. Stage 1 is characterised
by oral mucosa defect with bone exposure. However,
this lesion does not give any symptoms and no infec-
tion features are observed. In Stage 2, the lesion is pain-
ful with clinical features of infection. Stages 1 and 2 of
the disease are prophylactically treated. In Stage 3, the
lesions are as described for Stage 2, but additionally ac-
companied by: pathological bone fraction or fistula or
by extensive osteolysis. In Stage 3, surgical intervention
is applied to resect necrotically damaged tissues [10].
Subjects at risk of developing BONJ
Those at some risk of BONJ development include pa-
tients treated with bisphosphonates in oncological dos-
es, significantly exceeding the doses used in osteoporotic
therapy. These are patients with malignant neoplasms,
mainly carcinomas (mostly breast carcinoma, prostate
carcinoma or multiple myeloma), treated for disorders
of skeletal bone metabolism in the course of neoplas-
matic diseases: cancer-induced bone disease and meta-
static bone disease. Bisphosphonates (mainly zoledr-
onate and pamidronate) are administered intravenous-
ly. BONJ develops, on average, after 1.5–3 years of ther-
apy [2, 5–8, 11–13].
Risk factors for BONJ development
A number of risk factors for BONJ development have
been reported in the literature [4, 5, 8, 10–13]. The high-
er the number of such risks in a given patient, the high-
er the risk of BONJ occurrence. Risk factors for BONJ
development include:
— malignant neoplasmatic disease (mainly in the course
of multiple myeloma and breast carcinoma, where
the prevalence of BONJ cases amounts to 1–10%
of BP-treated patients);
— antineoplasmatic therapy (BPs, chemotherapy);
— changes within the oral cavity of different charac-
ter: surgical procedures, mainly tooth extractions
(38–80% of patients), dental diseases such as car-
ies(29% of patients), periodontitis (84% of patients),
poor oral hygiene, poorly fixed dentures, traumas
in the oral cavity;
— the presence of a toothless section in the mandible
or the maxilla;
— intravenous BP administration (with i.v. administration,
BP bioavailability is markedly higher: 50% of the drug
becomes incorporated as opposed to 1% with oral BP);
— corticosteroid therapy (mainly dexamethasone);
— alcohol;
— smoking;
— concomitant diseases: anaemia, diabetes, obesity,
renal insufficiency, rheumatoid arthritis, immuno-
suppression;
— female gender (in women, the incidence of BONJ is
eight times that of men);
— old age (the risk of BONJ development increases by
1% with each life decade).
Table I. BONJ staging and treatment strategies
Tabela I. Stopnie zaawansowania osteonekrozy żuchwy i metody ich leczenia
BONJ intensity stage Definition Treatment
Stage 1 — oral mucosa defect with bone exposure — prophylactic (mouth washing with 0.12%
— lack of symptoms chlorhexidine solution)
— no infection features
Stage 2 — oral mucosa defect with bone exposure — prophylactic  (mouth washing with 0.12%
— painfulness chlorhexidine solution and antibiotic therapy)
— clinical features of infection
Stage 3 — oral mucosa defect with bone exposure — surgical (resection of necrotically changed tissues)
— painfulness — antibiotic therapy
— clinical features of infection
— additionally one or more of these symptoms:
pathological fracture, fistula, osteolysis involving
e,g. the lower edge of the mandible
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BONJ’s pathogenesis
In the pathogenesis of BONJ, a multifactorial model is
taken into consideration, in which the following fac-
tors are specified:
— a different sensitivity of the stomatognathic system
vs. other areas of the skeleton;
— bone metabolism disorders;
— infectious factor;
— a toxic effect of BPs on soft tissues in the oral cavity;
— genetic factors;
— disorders in angiogenesis [2, 4, 8, 11, 12, 14–17].
BONJ’s pathogenesis remains unexplained.
Sensitivity of the stomatognathic
system [2, 4, 8, 14, 16]
Because of the continuous impact of chewing forces,
the jaws are characterised by higher bone metabolism
than other areas of the skeleton (e.g. 10–20% higher than
in the femoral bone). This higher bone metabolism is
necessary to repair chewing-related microfractures. On
the other hand, a higher bone metabolism requires bet-
ter vascularisation, which, in the therapy with bisphos-
phonates, is responsible for their higher concentrations
in bone tissue. Additionally, oral mucosa is thin and
susceptible to injuries and damage, which facilitates
bacterial access to bones. These circumstances may sup-
port BONJ development.
Bone metabolism disorders exerted
by BP effects [2, 4, 8, 11, 14, 16]
It is known that bisphosphonates inhibit bone resorp-
tion by suppressing osteoclasts via apoptosis. It slows
the rate of bone metabolism and reduces bone tissue
vascularisation, which in turn inhibits the replacement
of the old osseous tissue by new bone structures, lead-
ing to an accumulation of microfractures. Further dam-
age to oral mucosa gives way to bacterial penetration,
facilitating BONJ development.
Infection factor [4, 16]
Infection is a constant component of BONJ (Actinomy-
ces is typically identified). Periodontitis is also observed
in most patients with BONJ, while BONJ-associated
delayed wound healing, as mentioned in the definition
of this medical condition, encourages bacterial pene-
tration into bone.
Toxic effects of BPs on soft tissues
in the oral cavity [15]
A new hypothesis regarding BONJ development was pre-
sented in Davos in March 2010. This hypothesis assumes
toxic BP effects on oral soft tissues. An in vitro model was
used to evaluate BP effects on various cell lines, demon-
strating a suppressive effect of BPs on squamous epithe-
lial cells, an effect which is responsible for the delayed
healing process of oral mucosa defects, bacterial penetra-
tion and, finally, for BONJ development. Of the available
bisphosphonates, clodronate, a nitrogen-free BP,  has not
yet shown any inhibitory effect for squamous epithelial
cells; neither have any BONJ cases been recorded in the
world following clodronate administration. Regarding
nitrogen-containing BPs, three drugs have been evaluat-
ed, for which cases of BONJ development have been not-
ed in the world. The strongest cell-suppressing effect has
been demonstrated by zoledronate (Table II).
Genetic factors [12, 17]
In 2009, a report was published discussing a probable
role for genetic factors in BONJ development. In pa-
tients with multiple myeloma, receiving BPs by intra-
venous administration, polymorphism of the CYP2C8
gene was observed. This gene is associated with me-
tabolism of medicinal agents in the liver. However, it is
known that BPs are not metabolised in the liver, so an-
other location should be considered when searching for
the causes of BONJ development. The CYP2C8 gene is
also connected with the arachidonic acid cycle and plays
some role in vascularisation control. Perhaps then it is
responsible in the mandible for its worse vascularisa-
tion and, in consequence, for an increased risk of BONJ
development (by as much as 12.5 times).
Angiogenesis disturbances [2, 11]
Disturbances in angiogenesis are the least probable
BONJ development related factors. In the oncological
Table II. Influence of bisphosphonates (BPs) on different cell types
Tabela II. Wpływ bisfosfonianów (BP) na różne linie komórkowe
BP type Osteoclasts Fibroblasts Squamous epithelial cells BONJ
Clodronate N(–) + weakly + – none
Ibandronate N(+) ++ ++ ++ reported
Pamidronate N(+) +++ +++ +++ reported
Zoledronate N(+) ++++ ++++ ++++ reported
N(–) nitrogen-free BP; N(+) nitrogen-containing BP; suppressive effect + ; – no suppressive effect
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aspect, BPs inhibit tumour angiogenesis, induce apop-
tosis of neoplasmatic cells and suppress their adhesion
to the osseous tissue, thus inhibiting metastases. In this
respect, BPs would then negatively affect the bone tis-
sue, reducing its vascularisation, which would conse-
quently lead to lower bone metabolism and BONJ de-
velopment. However, this effect does not cause osteone-
crosis in any other part of the skeleton, while drugs oth-
er than BPs with antiangiogenic activity do not cause
mandibular osteonecrosis at all. Moreover, it has been
demonstrated on an animal model that angiogenesis in
the osseous tissue remains normal during BP therapy.
BONJ prevention
In 2009, German recommendations were published re-
garding BONJ prevention [5]. Prior to BP therapy on-
set in oncological doses, the patient should be referred
to a dentist for oral cavity control and, if necessary, den-
tal procedures. Patients should be informed of the need
for oral hygiene compliance and asked to regularly at-
tend the dentist (every six months), avoid surgical pro-
cedures within the oral cavity, stop smoking and re-
duce alcohol consumption. If any surgery is required
in the course of BP therapy, BP withdrawal should be
considered for 6-8 weeks before and after surgery, while
antibiotic therapy should be implemented on the day
before the procedure.
Similar recommendations can be found in other lit-
erature reports regarding BONJ prophylactics and ther-
apy [2, 4, 6–8, 11, 12, 16].
The incidence of BONJ
At the Congress in Davos in March 2010, Prof. D. Felsen-
berg presented German data concerning the cases of
BONJ, based on the German Register of this condition
[18]. This Register contains data of BP-treated patients
including: 84.4% for oncological reasons,(mainly pa-
tients with breast carcinoma, prostate carcinoma or with
multiple myeloma), 4.3% for osteoporosis, 4% simulta-
neously for oncological reasons and osteoporosis, and
7.3% for other reasons. The most frequently used bis-
phosphonate is zoledronate (63.9% of treated patients),
followed by pamidronate (15.3%), ibandronate (9.5%),
and alendronate (3.8%), with other BPs below 1%.
The incidence of BONJ in patients with malignant
neoplasms, i.e. treated with BP in oncological doses,
amounts in Germany to 1–2% (BONJ affects one or two
in every 100 treated patients). The occurrence of BONJ
was in those patients preceded by tooth extraction
(33%), poorly matched dentures (10%), periodontitis
(8%) or root canal treatment (4%).
The incidence rate of BONJ in BP-treated patients
for osteoporosis is very low, 0.0028%, i.e. it affects one
patient in every 36,000.
American data shows the incidence of BONJ to be
also low [2]. In 2005, alendronate belonged to the group
of 50 drugs most frequently prescribed in the United
States (20 million times), while only 170 cases of BONJ
were noted in the course of its use. During that same
year, 12 cases of BONJ were recorded for risedronate,
which is among the 100 most frequently prescribed
drugs (almost 10 million times).
The European position regarding BONJ
in the course of osteoporosis treatment
In 2008, the working group of researchers at the World
Health Organisation (WHO), chaired by Prof. R. Rizzo-
li, published their statement regarding BONJ in BP-
treated patients for osteoporosis [4]. This was formulat-
ed on the basis of a thorough review of the medical lit-
erature in  English  published 1995–2006. This paper
presents the definition, pathogenesis, risk factors and
methods of BONJ prophylactics and treatment, as dis-
cussed above.
Based on epidemiological data, it was determined
that the risk for BONJ development in BP-treated pa-
tients with osteoporosis is very low, amounting to one
case per 20,000–110,000 patient-years. Nevertheless,
a patient’s attention should be drawn to prophylactic
activities (oral hygiene and regular visits to the dentist).
If BONJ is diagnosed, it is usually at the first or second
stage of disease progression, and prophylactic manage-
ment is then most often effective.
BONJ summary
1. BONJ is a rare or very rare but serious condition con-
cerning mostly patients who receive BPs in onco-
logical, intravenous doses for at least, 1.5–3 years.
2. BONJ is a multi-factorial condition of still undeter-
mined pathogenesis.
3. The risk of BONJ depends on a number of issues, of
which the significant factors include: BP dose and
the route of administration, therapy duration, con-
comitant diseases, hygiene status and surgical pro-
cedures in the oral cavity.
4. In osteoporosis, it is a minor problem of very little
significance.
The most recent data on ONJ
Very recently, new data on ONJ has been published, slight-
ly modifying the views presented in the paper above.
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This new information is related to a new medical agent,
used in the therapy of osteoporosis and malignant neo-
plasmatic diseases. This new drug is denosumab (Prolia,
AMGEN). It is a monoclonal antibody against the ligand
for the RANK receptor of osteoclasts, the effect of which
is bone resorption inhibition [1]. This newer therapeutic
option has a different mechanism of action to BPs.
Denosumab in oncological doses and ONJ
In 2009, data was published of the almost three-year
use of denosumab or zoledronate in oncological doses,
administered to 2,046 women with breast cancer and
bone metastases [19]. In a performed evaluation of re-
sults, the incidence of ONJ was also considered. It was
found that ONJ could occur during therapy with de-
nosumab. This was an equally rare phenomenon, af-
fecting less than 1% of treated women, while the inci-
dence of ONJ did not significantly differ for either drug
(p = 0.39) (Table III). Similar data, presented by the
AMGEN company [20], has indicated that the incidence
of ONJ in patients treated with oncological doses is iden-
tical for both drugs, amounting to 0.6% (Table III).
Denosumab in the therapy
of osteoporosis and ONJ
In 2009, results were published of the FREEDOM pro-
spective study of denosumab application [21]. The study
comprised 7,868 women aged 60–90 with indications
for osteoporosis therapy. The patients were treated with
denosumab (60 mg subcutaneously every six months
for three years) and compared to a placebo group. Not
a single case of ONJ was noted during the three-year
observation period.
Summary
It has become clear that ONJ may occur not only when
BPs are used, but in therapy with denosumab as well,
i.e. drugs of different mechanisms of action. Both groups
of medical agents are applied in the therapy of bone
metabolic diseases. ONJ, associated with the use of the
above-mentioned drugs, is a rare condition and affects
patients treated with oncological doses. The problem is
of little significance in subjects treated for osteoporosis,
while the pathogenesis of ONJ still remains unexplained
and multifactorial.
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